Inventor profile of:

Matthew Albert

City:

Paris

Country:

France

Published Applications:

11

Last publication date:

2024-03-28

Top Assignees for applications by Matthew Albert

The entities that hold a legal rights for patent applications filed by inventor Albert Matthew:

Recent patent applications by Albert Matthew

Matthew Albert from Paris, FR has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-03-28
US20240100048A1
Human necessities

DIPEPTIDYLPEPTIDASE 4 INHIBITION ENHANCES LYMPHOCYTE TRAFFICKING, IMPROVING BOTH NATURALLY OCCURRING TUMOR IMMUNITY AND IMMUNOTHERAPY

#2 | 2022-04-21
US20220117960A1
Human necessities

Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy

#3 | 2020-08-27
US20200268859A1
Human necessities

Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy

#4 | 2018-08-16
US20180228881A1
Human necessities

Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy

#5 | 2017-09-21
US20170269084A1
Physics

Levels of CXCL10/IP-10 forms and soluble CD26/DPPIV activity as early predictive biomarkers for HIV/SIV associated mucosal inflammation and progression towards AIDS

#6 | 2015-09-03
US20150247853A1
Physics

Levels of CXCL 10/IP-10 forms and soluble CD26/DPPIV activity as early predictive biomarkers for HIV/SIV associated mucosal inflammation and progression towards AIDS

#7 | 2015-03-12
US20150071873A1
Human necessities

Cancer Treatment by Immunotherapy With BCG or Antigenically Related Non-Pathogenic Mycobacteria

#8 | 2012-07-05
US20120171158A1
Chemistry; metallurgy

METHODS OF USING sIP-10, CD26 INHIBITORS AND CXCR3 LEVELS IN A SAMPLE TO ASSESS CLEARANCE OF INFECTION, RESPONSE TO INTERFERON THERAPY, AND TREATING CHRONIC INFECTIONS

#9 | 2010-02-18
US20100040577A1
Chemistry; metallurgy

Methods of using sIP-10, CD26 inhibitors and CXCR3 levels in a sample to assess clearance of infection, response to interferon therapy, and treating chronic infections

#10 | 2008-05-22
US20080119388A1
Chemistry; metallurgy

Methods of using sIP-10 to assess HCV clearance and/or response to interferon therapy

#11 | 2006-05-25
US20060110371A1
Chemistry; metallurgy

Control of indoleamine 2,3 deoxygenase expression and activity

InventorID:

1095293 ⎘